Zerodha (Trading & Demat Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
Zerodha (Trading & Demat Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
|
Track all the latest updates and news of Par Drugs IPO.
June 24, 2024 3:55:00 PM
Foresite Capital Management, Baker Brothers Life Sciences LP and AyurMaya Capital Management Fund LP are listed as principal shareholders in the Alumis IPO. Why Intel�s stock avoided the ...
Published by : MarketWatchJuly 15, 2024 8:42:00 PM
The lackluster enthusiasm in the U.S. IPO market continues, with investor attention now focused on Q2 earnings. Nevertheless, the pipeline looks steady, with hospital operator Ardent Health (ARDT) and ...
Published by : Seeking Alpha on MSNJuly 19, 2024 11:39:00 AM
Cell therapy startup Artiva Biotherapeutics will go public on Friday morning in the 11th biotech IPO this year. Its Wall Street debut adds to the industry's modest rebuilding in 2024 following a ...
Published by : ENDPOINTS NEWSJuly 17, 2024 8:15:00 AM
Actuate Therapeutics has set out plans for a modest $52 million IPO as the biotech seeks to fund a pair of trials for its glycogen synthase kinase-3 beta (GSK-3�) drug. The Texas- and Ireland-based ...
Published by : FierceBiotechJune 24, 2024 3:30:00 AM
The company plans on starting a late-stage clinical trial of its drug in the second half of this year in psoriasis patients. Alumis Inc., a South San Francisco biotech company looking to take an ...
Published by : The Business JournalsJuly 18, 2024 11:11:00 PM
The offering comes days after the publication of a paper showing what analysts said was early proof that �off-the-shelf� cell therapies can treat inflammatory diseases.
Published by : BioPharma DiveJuly 18, 2024 8:01:36 PM
Ardent Health Partners (ARDT), a for-profit hospital operator, raised $192M through a downsized IPO that priced below its previously stated range. Read more here.
Published by : Seeking Alpha on MSNJuly 8, 2024 7:57:10 PM
Akums Drugs and Pharmaceuticals has received Sebi approval to raise funds through an initial public offering (IPO), an update with the markets regulator showed on Monday ...
Published by : Press Trust of India on MSNJuly 15, 2024 3:30:00 AM
Calliditas Therapeutics has just pulled off the largest biotech IPO in Europe this year and is using it to bring a drug for a rare kidney disease to market. Richard Staines caught up with CEO ...
Published by : pharmaphorumJuly 18, 2024 2:06:00 PM
slowing the IPO pace in the drug sector. But some pharmaceutical companies with pressing needs for capital are still keen to list there, after tighter rules made mainland exchanges a tougher option.
Published by : Benzinga.comThe allotment status of Par Drugs and Chemicals Limited IPO is now available online. The public issue of Par Drugs IPO was open on May 3, 2019 and closed for subscription on May 8, 2019. The equity shares of the company to be list at NSE SME.
The IPO Shares of Par Drugs and Chemicals Limited IPO are proposed to list on Thursday, May 16, 2019 at NSE SME. The public issue of Par Drugs IPO was opened on May 3, 2019 and closed for subscription on May 8, 2019. Par Drugs IPO Listing Date and Information:
Par Drugs and Chemicals Limited is entering in the capital market with an IPO of 1,700,000 Equity Shares of Rs 10 aggregating up to Rs 8.53 Crore. The price for the issue has been set at Rs 51 Per Equity Share.
Incorporated in 1999, Gujarat based Par Drugs and Chemicals Limited is engaged in the business of manufacturing and developing active pharma ingredients (API) for the Indian and international markets. APIs are used as the main ingredient in making tablets, capsules, and other finished dosages. The company also produces various antacid molecules which are in great demand in the market.
The issue opens on May 3, 2019 and closes for subscription on May 8, 2019. The equity shares of the company to be list at NSE SME.
The issue of Par Drugs and Chemicals Limited opens on May 3, 2019 and closes for subscription on May 8, 2019. The equity shares of the company to be list at NSE SME. The price for the issue has been set at Rs 51 Per Equity Share.
The Par Drugs IPO is proposed to open on May 3, 2019. The IPO application ends on May 8, 2019.
Retail investors can apply in the retail or non-institutional investor category from May 3, 2019 to May 8, 2019. The Par Drugs IPO can be applied online through Net Bank (ASBA method) or the stock broker (UPI method).
The Par Drugs IPO will open for subscription on May 3, 2019. The public issue will close on May 8, 2019.
Useful Articles
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|
|
RHP
